{"id":"allo-asc-dfu","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Pain at injection site"}]},"_chembl":{"chemblId":"CHEMBL472440","moleculeType":"Small molecule","molecularWeight":"262.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of allogeneic (donor-derived) adipose-derived stem cells that are administered to diabetic foot ulcer sites to stimulate angiogenesis, reduce inflammation, and promote tissue repair and re-epithelialization. These mesenchymal stem cells secrete paracrine factors and growth factors that enhance the wound healing microenvironment and restore tissue integrity in chronic, non-healing diabetic ulcers.","oneSentence":"ALLO-ASC-DFU is an allogeneic adipose-derived mesenchymal stem cell therapy that promotes wound healing and tissue regeneration in diabetic foot ulcers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:50.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic foot ulcers (DFU)"}]},"trialDetails":[{"nctId":"NCT04569409","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2020-07-14","conditions":"Diabetic Foot Ulcer","enrollment":104},{"nctId":"NCT03754465","phase":"PHASE2","title":"Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2019-01-02","conditions":"Diabetic Foot Ulcer","enrollment":66},{"nctId":"NCT06141811","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial","status":"RECRUITING","sponsor":"Anterogen Co., Ltd.","startDate":"2023-04-25","conditions":"Diabetic Foot Ulcer","enrollment":104},{"nctId":"NCT04590703","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2020-06-24","conditions":"Diabetic Foot Ulcer","enrollment":73},{"nctId":"NCT03370874","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2018-06-27","conditions":"Diabetic Foot Ulcer","enrollment":150},{"nctId":"NCT03183804","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-12-29","conditions":"Diabetic Foot Ulcer","enrollment":54},{"nctId":"NCT02619851","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-12-23","conditions":"Burn Injury","enrollment":20},{"nctId":"NCT02579369","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-12-08","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":2},{"nctId":"NCT03183934","phase":"","title":"A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2017-12-08","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":2},{"nctId":"NCT03183648","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2016-08-29","conditions":"Burn","enrollment":14},{"nctId":"NCT03183622","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-11","conditions":"Burn","enrollment":5},{"nctId":"NCT03183726","phase":"","title":"A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2016-01-11","conditions":"Diabetic Foot Ulcer","enrollment":4},{"nctId":"NCT02619877","phase":"PHASE2","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-10","conditions":"Diabetic Foot Ulcer","enrollment":59},{"nctId":"NCT02394873","phase":"PHASE1","title":"A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2015-03","conditions":"Burn","enrollment":5},{"nctId":"NCT02394886","phase":"PHASE1","title":"Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2014-11","conditions":"Diabetic Foot Ulcer","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic mesenchymal stem cells","Allogenic adipose-derived mesenchymal stem cells","Hydrogel sheet containing allogenic mesenchymal stem cells","Hydrogel sheet containing Allogenic Mesenchymal Stem Cells"],"phase":"phase_3","status":"active","brandName":"ALLO-ASC-DFU","genericName":"ALLO-ASC-DFU","companyName":"Anterogen Co., Ltd.","companyId":"anterogen-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ALLO-ASC-DFU is a small molecule being studied in a Phase 2 clinical trial for its efficacy and safety in treating Diabetic Foot Ulcer and Dystrophic Epidermolysis Bullosa. The trial is comparing ALLO-ASC-DFU to standard therapy and a vehicle sheet.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":8,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}